Overview
Targeting the JAK/STAT Pathway in Immune-mediated Inflammatory Diseases: Current and Future Directions
Targeting the JAK/STAT Pathway in Inflammatory Diseases
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Rheumatoid arthritis (RA) and inflammatory bowel disease (IBD) are chronic, systemic, autoimmune disorders characterized by inflammatory processes. There are numerous classes of therapies available to treat RA and IBD, and some patients achieve low disease activity or remission, yet a proportion of patients exhibits an inadequate response and/or discontinues therapy due to tolerability. As such, investigations into new targets and therapies, such as the janus kinase (JAK) inhibitors, continue. The introduction of JAK inhibitors further contributes to a growing armamentarium of therapies for these immune-mediated inflammatory diseases. Evolving strategies for employing the JAK inhibitors present a decision-making challenge to clinicians who treat these patients.
This activity is intended for gastroenterologists, rheumatologists
and other clinicians interested in learning more about the JAK/STAT signaling pathway.
and other clinicians interested in learning more about the JAK/STAT signaling pathway.
This clinical commentary features a video-based digital classroom which including a didactic clinical review, faculty discussion, and an augmented reality MOA animation. This educational activity will provide clinicians with clinical data and expert opinions to aid them in providing the best possible care to their patients with RA and IBD.
Upon completion of this activity, participants will be able to:
• Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of
immune-mediated inflammatory diseases
• Evaluate the use of JAK inhibitors in immune-mediated inflammatory diseases such as RA and IBD
• Interpret clinical trial efficacy and safety data of JAK inhibitors under investigation across inflammatory diseases
• Outline approaches to educating patients on the role of JAK inhibition, including efficacy and safety data
• Discuss the role of the JAK/STAT signaling pathway in the inflammation and disease progression of
immune-mediated inflammatory diseases
• Evaluate the use of JAK inhibitors in immune-mediated inflammatory diseases such as RA and IBD
• Interpret clinical trial efficacy and safety data of JAK inhibitors under investigation across inflammatory diseases
• Outline approaches to educating patients on the role of JAK inhibition, including efficacy and safety data
Sponsored by the Academy for Continued Healthcare Learning.
Supported by an educational grant from Gilead Sciences, Inc.
Russell Cohen, MD (Moderator)
Professor of Medicine
Directory, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
University of Chicago Medical Center
Chicago, Illinois
Professor of Medicine
Directory, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
University of Chicago Medical Center
Chicago, Illinois
William Rigby, MD
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Joel Pekow, MD
Assistant Professor of Medicine
Section of Gastroenterology, Hepatology and Nutrition
University of Chicago Medicine and Biological Sciences
Chicago, Illinois
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Russell Cohen, MD
Speakers’ Bureau: AbbVie, Takeda Pharmaceuticals, Inc.
Consultant/Advisory Board: AbbVie, Celgene Corporation, Entera Health, Inc., Hospira, Janssen, Pfizer, Inc., Sandoz Biopharmaceuticals, Takeda Pharmaceuticals, Inc., UCB S.A.
Clinical Investigator: AstraZeneca, Celgene Corporation, Gilead Sciences, Inc., MedImmune, Mesoblast Ltd., Osiris Therapeutics, Inc., Pfizer Inc., Receptos, RedHill Biopharma, Sanofi-Aventis, USB S.A.
The following financial relationships have been provided:
Russell Cohen, MD
Speakers’ Bureau: AbbVie, Takeda Pharmaceuticals, Inc.
Consultant/Advisory Board: AbbVie, Celgene Corporation, Entera Health, Inc., Hospira, Janssen, Pfizer, Inc., Sandoz Biopharmaceuticals, Takeda Pharmaceuticals, Inc., UCB S.A.
Clinical Investigator: AstraZeneca, Celgene Corporation, Gilead Sciences, Inc., MedImmune, Mesoblast Ltd., Osiris Therapeutics, Inc., Pfizer Inc., Receptos, RedHill Biopharma, Sanofi-Aventis, USB S.A.
William Rigby, MD
Consulting Agreements: Bristol-Myers Squibb, Pfizer Inc., Roche
Joel Pekow, MD
Sources of Funding for Research: AbbVie, Takeda Pharmaceuticals, Inc.
Consultant/Advisory Board: Janssen, Pfizer, Inc., Verastem Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: JAK inhibitors under investigation for RA and IBD.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
